Statistics from Altmetric.com
The Authors’ reply
We read with interest the correspondence by Papaila et al1 concerning our work on cardiovascular outcomes among patients with chronic myeloid leukaemia (CML). They raise several important points. We agree that the characteristics of patients prescribed tyrosine kinase inhibitors (TKI) are likely to have evolved since the introduction of these transformative therapies. In our research, we found that prior to the regulatory approval of TKI, the incidence of adverse cardiovascular events among patients with CML was lower than among age-matched and …
Contributors All authors have contributed to the content of this letter.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.